SEC Form 4 · accession 0001213900-26-100877
Inmune Bio, Inc. · INMB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Sapirstein
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 1:44 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001711754
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $2.33 | Sep 15, 2026 | A | 100,000 | A | — | Sep 14, 2036 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1Represent an initial award of options in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc. Granted pursuant to the Issuer's Third Amended and Restated 2021 Stock Incentive Plan. The options will vest in 36 equal installments over three (3) years (1/36 per month) beginning one month after the grant date until the option is 100% vested which shall occur on the three-year anniversary of the date of grant.